×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
How it Works
🎨
Pitch
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
How it Works
Pitch
Showcase
Demo
←
Home
/
Wiki
/
Mechanism: Disease Progression and Staging in Progressive Supranuclear
mechanism
3,633 words
KG: ent-dise-bfd8f32d
2026-03-24
kind:mechanism
section:mechanisms
state:published
Contents
Disease Progression and Staging in Progressive Supranuclear Palsy
⚙
Mechanism Info
Name
Disease Progression and Staging in Progressive Supranuclear Palsy
Summary
Page for Disease Progression and Staging in Progressive Supranuclear Palsy
Knowledge Graph
Related Hypotheses (15)
Purinergic Signaling Polarization Control
Score: 0.55
Mechanosensitive Ion Channel Reprogramming
Score: 0.51
Lipid Droplet Dynamics as Phenotype Switches
Score: 0.46
Targeted APOE4-to-APOE3 Base Editing Therapy
Score: 0.53
APOE4 Allosteric Rescue via Small Molecule Chaperones
Score: 0.54
Selective APOE4 Degradation via Proteolysis Targeting Chimer
Score: 0.59
Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides
Score: 0.51
Competitive APOE4 Domain Stabilization Peptides
Score: 0.56
Interfacial Lipid Mimetics to Disrupt Domain Interaction
Score: 0.46
Glymphatic-Mediated Tau Clearance Dysfunction
Score: 0.55
Dual-Circuit Tau Vulnerability Cascade
Score: 0.50
Dopaminergic Ventral Tegmental-Hippocampal Circuit Protectio
Score: 0.49
APOE4-Selective Lipid Nanoemulsion Therapy
Score: 0.49
APOE Isoform Expression Across Glial Subtypes
Score: 0.48
APOE Isoform Conversion Therapy
Score: 0.44
Show 10 more
Related Analyses (30)
4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · archived
Do tau strains or regional cellular environments primarily d
neurodegeneration · failed
4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · completed
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · archived
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · failed
Selective vulnerability of entorhinal cortex layer II neuron
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived
Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · archived
Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · archived
Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived
Neuroinflammation resolution mechanisms and pro-resolving me
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · archived
Mitochondrial transfer between neurons and glia
neurodegeneration · archived
Protein aggregation cross-seeding across neurodegenerative d
neurodegeneration · archived
Mechanistic role of APOE in neurodegeneration
neurodegeneration · archived
Sleep disruption as cause and consequence of neurodegenerati
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
Synaptic pruning by microglia in early AD
neurodegeneration · archived
Mitochondrial transfer between astrocytes and neurons
neurodegeneration · archived
Epigenetic clocks and biological aging in neurodegeneration
neurodegeneration · archived
Perivascular spaces and glymphatic clearance failure in AD
neurodegeneration · archived
TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · archived
Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · failed
Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · failed
Gene expression changes in aging mouse brain predicting neur
neurodegeneration · archived
Gene expression changes in aging mouse brain predicting neur
neurodegeneration · failed
Show 25 more
Related Experiments (25)
s:** - Single-cell RNA-seq to measure editing efficiency acr
falsification · proposed · Score: 0.40
Metabolic Pathway-Targeted Therapy in ALS
clinical · proposed · Score: 0.40
ALS Progression Rate Heterogeneity — mechanism and biomarker
clinical · proposed · Score: 0.40
ALS Regional Onset and Spread: Network-Level Staging Model
clinical · proposed · Score: 0.40
Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk
clinical · proposed · Score: 0.40
Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri
clinical · proposed · Score: 0.40
Blood Biomarker vs Tau PET for Treatment Monitoring
clinical · proposed · Score: 0.40
Brainstem Circuit Modulation for PSP
clinical · proposed · Score: 0.40
Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FT
validation · proposed · Score: 0.40
C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study
clinical · proposed · Score: 0.40
Environmental Exposure Causal Attribution in ALS — Experimen
validation · proposed · Score: 0.40
FXTAS Phenotypic Penetrance: Why Only 40% of FMR1 Premutatio
validation · proposed · Score: 0.40
Microbiome-Gut Barrier Signatures in ALS — Experiment Design
clinical · proposed · Score: 0.40
N-of-1 Clinical Trial Design for CBS/PSP
clinical · proposed · Score: 0.40
Pre-Symptomatic Tau Detection in MAPT Mutation Carriers
clinical · proposed · Score: 0.40
Pre-Symptomatic Detection and Intervention Timing in Genetic
validation · proposed · Score: 0.40
Progranulin Replacement Therapy for FTD — Vector Development
clinical · proposed · Score: 0.40
Mechanism: Progranulin Loss and TDP-43 Pathology in FTD
validation · proposed · Score: 0.40
PSP and CBS Biomarker Validation Study
clinical · proposed · Score: 0.40
Sleep and Respiratory Network Interaction in ALS — Experimen
clinical · proposed · Score: 0.40
TDP-43 PET Ligand Development for FTD and ALS
clinical · proposed · Score: 0.40
Viral and Post-Infectious Mechanisms in ALS — Experiment Des
clinical · proposed · Score: 0.40
Tau depletion effects on neuronal development in primary cul
exploratory · proposed · Score: 0.90
Microtubule domain analysis in adult axons
exploratory · proposed · Score: 0.80
FTLD-Tau vs FTLD-TDP In Vivo Biomarker Differentiation
clinical · proposed · Score: 0.40
Show 20 more
See Also (15)
ALS Therapeutic Landscape — Programs by Phase and Modal
disease · Pages share 3 hypotheses
Wnt/β-Catenin Signaling Pathway in Neurodegeneration
mechanism · Pages share 3 hypotheses
WNK1-Bilirubin Signaling in Neuroinflammation and Neuro
mechanism · Pages share 3 hypotheses
vip-vasoactive-intestinal-peptide-signaling-neurodegene
mechanism · Pages share 3 hypotheses
VEGF Signaling and Cerebral Angiogenesis in Neurodegene
mechanism · Pages share 3 hypotheses
Vagus Nerve Pathway in Neurodegeneration
mechanism · Pages share 3 hypotheses
Ubiquitin-Proteasome System Dysfunction in Neurodegener
mechanism · Pages share 3 hypotheses
ubiquitin-proteasome-dysfunction-neurodegeneration
mechanism · Pages share 3 hypotheses
Transdiagnostic Proteomic Changes in Neurodegeneration
mechanism · Pages share 3 hypotheses
Transdiagnostic Proteomic Changes in Neurodegeneration
mechanism · Pages share 3 hypotheses
Therapeutic Targets in Neurodegeneration
mechanism · Pages share 3 hypotheses
Tertiary Lymphoid Organs in Neurodegeneration
mechanism · Pages share 3 hypotheses
TBK1 Autophagy and Neuroinflammation ALS/FTD Causal Cha
mechanism · Pages share 3 hypotheses
Tau Seeding and Propagation Pathway
mechanism · Pages share 3 hypotheses
T-Cell Dysfunction in Neurodegeneration
mechanism · Pages share 3 hypotheses
Show 10 more